References to primary literature
- References of special interest have been highlighted as: = of interest
- DELGADO-ESCUETA AV, WARD JR AA, WOODBURY DM, PORTER RJ: Basic mechanisms of the epilepsies: molecu-lar and cellular approaches. Adv. Neurrol. (1986) 44:1–20.
- PEDLEY TA: Pediatric aspects of epilepsy. Epilepsia(1987) 28(Suppl 1):S1–S109.
- RALL TW, SCHLEIFER LS: Drugs effective in the therapy of the epilepsies. In: Goodman and Gilman 's The Pharma-cological Basis of 7beraeutics (1990). GOODMAN-GILMAN, RALL, NIES, TAYLOR (Eds.), McGraw Hill, p 436.
- BURNHAM WM: Antiseizure drugs. In: Principles of Nedical Pharmacolgy (1989). KALANT, ROSCHLAU (Eds.), BC Decker, Inc, p 203.
- PORTER RJ, MELDRUM BS: Anti-epileptic drugs. In: Basic and Clinical Pharmacology (1992). KATZUNG BG (Ed.), Lange, p331.
- SHELTON RC, GREBB JA, FREED Wj: Induction of seizures in mice by intra-cerebrovontricular administration of the calcium channel agonist. Brain Res. (1987) 402:399–402.
- RAMPE D, FERRANTE J, TRIGGLE DJ: The actions ofdiazepam and diphenylhydantoin on fast and slow Ca2 2' uptake processes in guinea pig cerebral cortex synaptogomes. Can. J. Physiol. Pbarmacol. (1987) 65:538–543.
- OTS ME, YAKSH TL, ANDERSON RE, SUNDT JR TM: Effect of dihyciropyridines and diphenylalkylarnines on pen-tylenetetrazol induced seizures and cerebral blood flow in cats. J. Neurosurg. (1987) 67:406–413.
- MEYER FB, ANDERSON RE, SUNDT JR TM, YAKSH TL, SHARBROUGH FW: Suppression of pentylenetetrazoie seizures by oral administration of a dihydropyridine Ca2. antagonist. Epilepsia (1987) 28:409–414.
- MARTIN LL, TEGELER JJ: Anti-anxiety agents and anticonvulsants. In Annual Reports in Medicinal Chemistry, RC Allen (Ed.), Academic (1988) pp 22–28.
- This reference highlights the compounds currently under clinical investigation.
- FAINGOLD CL, BROWNING RA: Mechanisms of anticon-vulsant drug action L Drugs primarily used for gener-alized tonic-clonic and partial epileps ies Eur.J. Paediatr. (1987) 146:2–7.
- FAINGOLD CL, BROWNING RA: Mechanisms of anticon-vulsant drug action II. Drugs primarily used for absence epilepsy. Eur. J. Paediatr. (1987) 146:8–14.
- LOSCHER W: Neurophysiologic and neurochemical principles of the effect of anticonvulsants. Fortschr. Neurol. Psycbiatr. (1987) 55:145–157.
- LEHMANN J, SCHNEIDER JA, WILLIAMS M: Excitatory amino acids and mammalian CNS function. Ann. Rep. Med. Chem. (1987) 22:31.
- WATKINS JC, OLVERMANAgonists and antagonistsfor excitatory amino acid Receptors. Trends Neurosci. Special issue (1987) 10:263–265.
- MELDRUM BS, EVANS MC, SWAN JH, SIMON RP: Protection against hypoxic/ischaemic brain damage with excita-tory amino acid antagonists. Med. Biol. (1987) 65:153–157.
- FOSTER AC, FAGG GE: Neurobiology. taking apart NMDA receptors. Nature (1987) 329:395–396.
- LEANDER JD, LAWSON RR, ROBERTSON DW: Anticonvul-sant effects of a novel aminobenzatnide (LY201116) in mice. Neuropharrnacol. (1989) 27:623–628.
- MELDRUM BS, PORTER RJ (EDS). New anticonvulsant drugs. In: Current Problems in Epilepsy (1986). John Libby (1986) Vol 4.
- CHADWICK D: The modern treatment of epilepsy. Brit. J. Hosp. Med. (1988) 39:104-107 and 110–111.
- HRIB NJ, MARTIN LL: Anti-anxiety agents and anticonvulsants. In Annual Reports in Medicinal Chemistry. Allen RC (Ed.) Academic Press (1989) pp 14–20.
- This reference highlights the compounds currently under clinical investigation.
- HAIGH JRM, PULLAR T, GENT JP, DAILLEY C, FEELY M: N-Desmethylclobazatn: a possible alternative to do-bazam in the treatment of refractory epilepsy? Brit. J. Clin. Pbarmacol. (1987) 23:213–218.
- MCDONALD JW, SILVERSTEIN FSJOHNSTON MV: MK-801 protects the neonatal brain from hypoxic-ischemic Damage. Euro. J. Pbarmacol. (1987) 140:359–361.
- BARNES DM: Drug may protect brains of heart attack victims. Science (1987) 235:632–633.
- BLAKE PA, YAMAGUCHI S, THURKAUF A, ROGAWSKI MA: AnticonvuLsant 1-phenylcycloalkylainines: two ana-logues with low motor toxicity when orally adminis-tered. Epilepsia Res. (1992) 33:188–194.
- WILICER J, FIELDING S, DECOSIMO J, CHERNACK J, MALE-JKO E, STRUPCZEWSKI J: Anticonvulsant activity of HP654 [4[1-(4-Trifluoromethylphenyfilif-indazol-3-yl-piperidine- 1-carboxamide hydrobromide]. Pharma-cologist (1987) 143:Ab204.
- PAVIA MR, TAYLOR CP, HERSHENSON FM, LOBBESTALL SJ: 6- AllcoxyN,N-disubstituted-2-pyridinamines, an an-ticonvulsant agents. J. Med. Chem. (1987) 30:1210–1214.
- ALBERTSON TE, WALBY WF: The anticonvulsant action of A11R11748 on kindled amygdaloid seizures in rats. Epilepsy Res. (1987) 1:126–133.
- BARTOSZYK GD, HAMER M: The genetic animal model of reflex epilepsy in the mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype anti-epileptics. Pharmacol. Res. Comm. (1987) 19:429–440.
- KELLEY JL, KROCHMAL MP, LINN JA, MCLEAN EW, SOROKO FS: 6-(Alkylainino)-9-benzy1-9H-purines. a new class of anticonvulsant agents. J. Med. Chem. (1988) 31:606–612.
- BATES JF, PEAK L, SWEARENGEN ES, HALL TW, STANDIIILJ: CL 218-872 pretreatment and intervention block kainate-induced convulsions and neuropathy. Bebav. Neurosci (1988) 102:84–92.
- LEANDER JD, LAWSON RR, ROBERTSON DW: Anticonvul-sant effects of a novel arninobenzamide (LY201116) in mice. Neuropliarrizacol. (1988) 27:623–628.
- CLARK CR: Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyi) ben-zamide and prototype anti-epileptic drugs in mice and rats. Epilepsia (1988) 29:198–203.
- SARHAN S, CASARA P, KNODGEN B, SEILER N: 4(S)-4-Amino-5,6-heptadienoic acid (MDL 72483): a potent anticonvulsant GABA-T inhibitor. Neurochem. Res. (1991) 16:285–293.
- PHILLIPS OA, RNAUS EE: Synthetic and anticonvulsantactivity of 3-(3'-trifluoromethylphenory)-pyridines and dihydropyridines. Drug Design and Delivery (1991) 7:279–286.
- GARSKE GE, PALMER GC, NAPIER JJ, GRIFFITH RC, FREED- MAN LR, HARRIS EW, RAY R, MCGreedy SA, Blosser JC, Woodhead JH, White HS, Swinyard EA: Preclinical profile of the anticonvulsant remacemide and its enatiomers in the rat. Epilepsy Res. (1991) 9:161–174.
- Contains a discussion on Remacemide, currently under clnical trial for the treatment of epilepsy and other neurological disorders.
- DESARRO G, TRIMARCH1 GR, FEDERICO F, DESARRO A:Anticonvulsant activity of some calcium antagonists in genetically epilepsy prone rats. In: New Anti-epileptic Drugs (1991). PISANI, PERUCCA, AVANZINI, RICHENS (Eds.), Elsevier, pp 49–55.
- DESARRO GB, DESARRO A, TRIMARCHI GR, NISTICO G:Effects of some calcium antagonists upon the activity of common antileptic compounds on sound-induced seizures in DBA/2 mice. Gen. Pharmac. (1992) 23:75–82.
- TAYLOR CP, VERTANIAN MG, ANDRUSZKLEWICZ R, SIL-VERMAN RB: 3-Alkyl (ABA and 3-alkyl g,lutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. (1992) 11:103–110.
- WHITE HS, WOLF HH, SWINYARD EA, SKEEN GA, SOFIA RD: A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia (1992) 33:564–572.
- Discusses Felbamate, which has been recently approved by the FDA. Felbamate is recommended as mono and adjunct therapy in treat-ments with partial seizures, including those who are refractory to other treatments.
- LOSCHER W, SCHMIDT D: New drugs for the treatment of epilepsy. Curr. Opin. Invest. Drugs (1993) 2:1067–1095.